Determination of the malnutrition risk in overweight and obese patients with cardiovascular disease

Objective: Coronary artery disease (CAD) is the one of the leading cause of morbidity and mortality worldwide and statins are frequently prescribed in the treatment of CAD to help lower blood cholesterol levels. Since the main enzyme involved in the metabolism of statins is CYP3A4, we aimed to investigate the effect of CYP3A4 * 1B genotypes on plasma lipid profile in Turkish cardiovascular disease subject with and without obesity taking statin. Materials and Methods: The study group consisted of 85 cardiovascular disease patients who were prescribed statins and had routine biochemical analysis data. Polymerase chain reaction followed by restriction fragment length polymorphism (PCR-RFLP) assay were performed for genotyping of CYP3A4 *1B (rs2740574) polymorphism. Results: Genotype distribution of CYP3A4 *1B polymorphism was found for homozygous wild (AA) and homozygous polymorphic (GG) genotypes as 94.1% and 5.9% respectively. We did not detect patients with heterozygous genotype in our study group. We found that the mean LDL-c, TG and TC levels were higher in patients with CYP3A4 *1B GG compared to AA genotype. The frequency of CYP3A4 *1B GG genotype frequency (9.5%) was detected higher in the obese patients compared to the non-obese patients (7.7%) (χ2=0.037, p=0.85). Conclusions: Our results demonstrate that CYP3A4 *1B homozygous polymorphic genotype distribution tend to be higher in obese patients compared to non- obese patients with cardiovascular disease which may point *1B allele to have a slight effect on serum lipids during statin therapy. Additional studies with higher samples are needed for evaluating the role of CYP3A4 *1B on lipids in patients under statin therapy.

Download Full-text

SCREENING FOR DYSLIPIDEMIA AND EXPEDIENCE OF STATIN THERAPY FOR THE CITIZENS OF TRANSCARPATHIA VALLEY REGIONS WITH OVERWEIGHT AND OBESITY

International Journal of Medicine and Medical Research ◽

10.11603/ijmmr.2413-6077.2017.1.6879 ◽

2017 ◽

Author(s):

A. V. Kedyk ◽

M. V. Rishko ◽

O. O. Kutsyn

Keyword(s):

Statin Therapy ◽

Overweight And Obesity ◽

Obese Patients ◽

Microsoft Excel ◽

Atherogenic Dyslipidaemia ◽

Overweight Group ◽

Group 2 ◽

High Level ◽

Very High

Background. The lipid profiles of patients with overweight, obesity and healthy individuals, the citizens of Transcarpathia valley regions were analysed.Objective. The study was aimed at evaluation of dyslipidaemia frequency in patients with overweight and obesity, determination of expedience of statins prescription.Methods. All patients were divided into 2 groups: group 1 – patients with overweight; group 2 – patients with obesity of I and II degree. Estimation of lipid profile parameters was conducted by means of spectrophotometric device SIEMENS Dimension RxL Max. Statistical analysis of the data was conducted using Microsoft Excel 2007.Results. The patients with obesity had higher level of total cholesterol (6.03±0.53 mmol/l), lower HDL-C (1.15±0.07 mmol/l) and higher level of LDL-C (4.19±0.46 mmol/l) compare with overweight patients.In 46% of patients with overweight, dyslipidaemia was evidenced and required correction, 27% of them had high CVR and needed statin therapy, 19% of people with obesity had moderate CVR and didn’t need statins.77% of obese patients needed lipid correction, 54% of them with very high and averagely high level of CVR required statin therapy; 23% of people with obesity had moderate CVR and did not need statins.Conclusions. In the studied overweight and obese patients, atherogenic dyslipidaemia was established in 46% and 77% of cases respectively. Correction of dyslipidaemia with statin was compulsory for 27% of patients with overweight and for 54% with obesity.

Download Full-text

The value of blood serotonin for effective weight loss in obese women

Obesity and metabolism ◽

10.14341/omet2015331-35 ◽

2015 ◽

Vol 12 (3) ◽

pp. 31-35

Author(s):

Natal'ya Vadimovna Anikina ◽

Elena Nikolaevna Smirnova

Keyword(s):

Weight Loss ◽

Body Weight ◽

Clinical Laboratory ◽

Normal Weight ◽

Obese Patients ◽

Obese Women ◽

Endothelin 1 ◽

Excessive Accumulation ◽

Made In

Introduction. Obesity is a disorder of energy balance, which leads to excessive accumulation of fat. In recent years, many important discoveries were made in this field, including the discovery of hormones produced by adipose tissue and the identification of many of the central and peripheral pathways of energy balance.Objective. To study the levels of hormones that affect appetite and metabolism in women with obesity baseline and after weight loss while taking sibutramine.Materials and methods. The study included 56 women aged 42,9±9,5 years, with a BMI of 34,6±6,1 kg/m2. All patients underwent clinical, laboratory and instrumental examination. Hormonal study included determination of serotonin, leptin, ghrelin, endothelin-1, adiponectin.Results: In women with obesity we identified hyperleptinemia and increased serotonin levels. The decrease in body weight in patients receiving sibutramine was accompanied by lower levels of serotonin, leptin, ghrelin, endothelin-1, and increase of adiponectin.Conclusions: Obese patients have significantly elevated levels of leptin, serotonin, ghrelin compared to women of normal weight. Sibutramine treatment leads to a decrease in serotonin, leptin, ghrelin and is more effective in women with a BMI less than 36,5 kg/m2.

Download Full-text

Abstract 15004: Bariatric Surgery is Associated With Reduced Atherosclerotic Cardiovascular Disease Burden in Obese Patients With Type 2 Diabetes: A Propensity-matched Cohort Study

Circulation ◽

10.1161/circ.142.suppl_3.15004 ◽

2020 ◽

Vol 142 (Suppl_3) ◽

Author(s):

Francesca Watson ◽

Maddalena Ardissino ◽

Ravi J Amin ◽

Chanpreet Arhi ◽

Peter Collins ◽

...

Keyword(s):

Type 2 Diabetes ◽

Cardiovascular Disease ◽

Bariatric Surgery ◽

Disease Burden ◽

Atherosclerotic Cardiovascular Disease ◽

Obese Patients ◽

Matched Cohort ◽

All Cause Mortality

Introduction: Obesity is an increasingly prevalent global health issue and has a considerable disease burden, including numerous co-morbidities. Atherosclerotic cardiovascular disease (ASCVD) is one such co-morbidity associated with a high mortality rate and prevalence, especially in patients with obesity and concomitant Type 2 diabetes mellitus (T2DM). Bariatric surgery is an effective intervention for patients with obesity, shown to reduce overall cardiovascular disease risk. However, few studies have quantified the long-term impact of bariatric surgery on ASCVD outcomes in the context of key co-morbidities such as T2DM. Hypothesis: Bariatric surgery will improve long-term ASCVD outcomes in obese patients with T2DM. Methods: A nested, nationwide, propensity-matched cohort study was carried out using the Clinical Practice Research Datalink. The study cohort included 593 patients who underwent bariatric surgery and had no past history of ASCVD. A further 593 patients served as propensity-score matched controls. Patients were followed up for a median time of 47.2 months. The primary composite study endpoint was the incidence of ASCVD defined by a diagnosis of new coronary artery disease (CAD), cerebrovascular disease (CeVD), peripheral arterial disease (PAD), or other miscellaneous atherosclerotic disease. Secondary endpoints included all-cause mortality and the incidence of CAD, CeVD, and PAD individually. Results: Patients who underwent bariatric surgery had significantly lower rates of new ASCVD during follow-up (HR 0.53, CI 0.30-0.95, p=0.032). No significant difference was observed in rates of new CAD (HR 0.69, CI 0.32-1.46, p=0.331), CeVD (HR 0.23, CI 0.00-5.45, p=0.1760) and PAD (HR 0.55, CI 0.21-1.43, p=0.218). The bariatric surgery group also had a lower rate of all-cause mortality (HR 0.36, CI 0.19-0.71, p=0.003) compared to controls. Conclusions: In this study, bariatric surgery was associated with improved ASCVD outcomes, as well as lower all-cause mortality, in patients with obesity and T2DM. These findings support the use of bariatric surgery in treating obesity and reducing the burden of its related comorbidities.

Download Full-text